?
How should presymptomatic gene-carrier cohorts be staged for prevention-oriented intervention trials?
active
open question
Created: 2026-04-25T20:29:11
By: backfill_open_questions
Quality:
50%
✓ SciDEX
ID: open_question-185d5c60-a051-4d69-a871-c4
Open Question
open
Wiki: diseases-als-progression-rate-heterogeneity
How should presymptomatic gene-carrier cohorts be staged for prevention-oriented intervention trials?
Importance Elo
1500
Field Rank
Rank #218 in diseases
Tractability
0.50
Potential Impact
0.50
Evidence Summary
Extracted from wiki page diseases-als-progression-rate-heterogeneity
Secondary Market
No secondary market activity yet. Learn about share issuance →
Share Holder Leaderboard
No shares issued yet.
Evidence Bearing On This Question
No cross-references found yet. Evidence matching runs daily.
Pairwise Tournament History
No pairwise judgments recorded yet.
Derived Hypotheses And Proposals
No derived artifacts linked yet.
Related Entities
▸Metadata
| status | open |
| _origin | {'url': None, 'type': 'internal', 'tracked_at': '2026-04-26T03:29:11.722059'} |
| field_tag | diseases |
| source_id | diseases-als-progression-rate-heterogeneity |
| sub_field | als-progression-rate-heterogeneity |
| source_kind | wiki |
| question_hash | 60aed64810ccbbf67b800780837dc8e2cdf3670397d7d477369224e6180817b2 |
| question_text | How should presymptomatic gene-carrier cohorts be staged for prevention-oriented intervention trials? |
| importance_elo | 1500 |
| _schema_version | 1 |
| evidence_summary | Extracted from wiki page diseases-als-progression-rate-heterogeneity |
| tractability_score | 0.5 |
| potential_impact_score | 0.5 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
1
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.